Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-181a-2-3p mimics are synthetic double-stranded RNA oligonucleotides designed to simulate the biological activity of the endogenous mature microRNA miR-181a-2-3p. As a member of the miR-181 family, this specific strand (the 3p arm of the miR-181a-2 precursor) regulates gene expression post-transcriptionally by binding to the 3' untranslated regions (UTRs) of target mRNAs, leading to translational inhibition or mRNA degradation. In preclinical research, these mimics have demonstrated diverse roles: they inhibit oncogenicity in colon cancer by targeting Stimulator of Interferon Genes (STING), reduce cancer stem cell populations in cervical cancer by targeting SOX2, and provide protective effects in sepsis-induced acute kidney injury by targeting GJB2. Conversely, in gastric cancer, they have been associated with promoting progression via MYLK targeting. These molecules are primarily utilized as research tools to investigate microRNA function and potential therapeutic pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on miR-181a-2-3p mimics.